Xencor: Funding, Investors & Team (Sep 2026)
Xencor, Inc. provides protein engineering technology platforms in the biotechnology industry. Its products include antibody therapeutics, such as XmAb2513 for the treatment of relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma; XmAb5574, a humanized monoclonal antibody that targets the antigen CD19 for treatment of B cell malignancies; XmAb5592 for the treatment of myeloma; and XmAb5871 and XmAb7195, which are humanized monoclonal antibodies for the treatment of asthma and allergy. The company’s products also include XPro protein therapeutics, such as XPro1595, a dominant negative inhibitor for the treatment of multiple animal models of autoimmune and neuroinflammatory diseases.
Xencor has raised $226M across 2 funding rounds on record, the most recent an undisclosed round of $201M announced in Sep 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Xencor Company Profile and Key Stats
Latest funding round on record: Sep 2024.
Xencor Funding Rounds
Xencor raised $25.0M in a Post-IPO Equity announced in Nov 2021.
2.8 years later, an undisclosed round of $201M was announced in Sep 2024.
Xencor Founders and Leadership Team
No contact details are on record for this team yet.
Xencor Funding Compared to Other Biotechnology Startups
Xencor's latest round of $201M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Xencor in Biotechnology and Monrovia
Companies Similar to Xencor
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Xencor Funding FAQs
What does Xencor do?
Xencor, Inc. provides protein engineering technology platforms in the biotechnology industry. Its products include antibody therapeutics, such as XmAb2513 for the treatment of relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma; XmAb5574, a humanized monoclonal antibody that targets the antigen CD19 for treatment of B cell malignancies; XmAb5592 for the treatment of myeloma; and XmAb5871 and XmAb7195, which are humanized monoclonal antibodies for the treatment of asthma and allergy. The company’s products also include XPro protein therapeutics, such as XPro1595, a dominant negative inhibitor for the treatment of multiple animal models of autoimmune and neuroinflammatory diseases.
How much funding has Xencor raised?
Xencor has raised $226M across 2 rounds on record. The most recent is an undisclosed round of $201M announced in Sep 2024.
When did Xencor last raise funding?
Xencor's most recent funding round on record is an undisclosed round of $201M, announced in Sep 2024.
Who founded Xencor?
FundedIQ lists Bassil Dahiyat (Founder) at Xencor.
Where is Xencor headquartered?
Xencor is based in Monrovia, California, United States.
How many employees does Xencor have?
Xencor is in the 101-250 employee band.
How does Xencor's funding compare to other Biotechnology startups?
Xencor's latest round of $201M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Xencor Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Xencor is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.